A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
152: Long Term Remission in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients After Allogeneic Myeloablative Hematopoietic Cell Transplantation (HCT) Using Matched Related Donors: The 20 Year Experience at Stanford University and City of Hope National Medical Center
Biology of Blood and Marrow Transplantation
post-HCT (10-pre-HCT and 5-post-HCT) comprising the Imatinib group and the remaining 17-patients, who either never received Imatinib (n 5 13) or received it at time of relapse (n 5 4), were the non-Imatinib group. Overall survival and relapse-free survival at 2 years was 73% and 65% for the Imatinib group compared to 34% and 35% for the non-Imatinib group (p 5 0.14 and 0.1, respectively). However, the incidence of relapse for these two groups was 8% (95% CI: 0.00, 0.24) and 41% (95% CI: 0.17,doi:10.1016/j.bbmt.2007.12.161 fatcat:s2v7k3mambafxgj7kyge6ayupm